The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

Of the eight patients treated, three demonstrated a systemic complete response, three demonstrated a systemic partial response ... as part of a two-stage hepatectomy, the clinicians observed ...

Preliminary phase 1/1b dose expansion results of the bifunctional EGFR/TGFβ inhibitor ficerafusp alfa (BCA101) with pembrolizumab in patients with squamous cell carcinoma of the anal canal. GOBLET ...

Using best overall response (BOR) in patients with a measured response, the findings from a pooled analysis include: 18% objective response rate, or ORR (either a complete response or partial ...